Lake Hills Wealth Management LLC Invests $277,000 in Hims & Hers Health, Inc. $HIMS

Key Points

• Lake Hills Wealth Management LLC has invested approximately $277,000 in Hims & Hers Health, acquiring 5,547 shares during the second quarter.
• Hims & Hers reported a Q2 earnings EPS of $0.17, missing the consensus estimate of $0.18, with a year-over-year revenue increase of 72.6%.
• Recent analyst ratings indicate a consensus rating of "Reduce" for Hims & Hers, with price targets ranging from $30.00 to $48.00.

Lake Hills Wealth Management LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm bought 5,547 shares of the company's stock, valued at approximately $277,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of HIMS. Captrust Financial Advisors acquired a new position in Hims & Hers Health in the 4th quarter valued at $340,000. Cetera Investment Advisers grew its position in Hims & Hers Health by 11.1% in the 4th quarter. Cetera Investment Advisers now owns 14,628 shares of the company's stock worth $354,000 after purchasing an additional 1,466 shares during the last quarter. Janus Henderson Group PLC grew its position in Hims & Hers Health by 17.3% in the 4th quarter. Janus Henderson Group PLC now owns 80,069 shares of the company's stock worth $1,936,000 after purchasing an additional 11,800 shares during the last quarter. ProShare Advisors LLC grew its position in Hims & Hers Health by 61.2% in the 4th quarter. ProShare Advisors LLC now owns 57,801 shares of the company's stock worth $1,398,000 after purchasing an additional 21,939 shares during the last quarter. Finally, Two Sigma Advisers LP grew its position in Hims & Hers Health by 839.2% in the 4th quarter. Two Sigma Advisers LP now owns 524,100 shares of the company's stock worth $12,673,000 after purchasing an additional 468,300 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HIMS has been the topic of several research analyst reports. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Zacks Research lowered shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a report on Monday, June 23rd. Morgan Stanley reissued an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. Finally, Truist Financial cut their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a report on Monday, August 18th. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Stock Performance

NYSE HIMS traded up $1.54 on Friday, hitting $57.74. 36,152,647 shares of the stock were exchanged, compared to its average volume of 27,039,632. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The business's fifty day moving average is $50.71 and its 200 day moving average is $45.69. Hims & Hers Health, Inc. has a 52 week low of $15.73 and a 52 week high of $72.98. The company has a market capitalization of $13.05 billion, a PE ratio of 72.18, a P/E/G ratio of 3.91 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same period last year, the company posted $0.06 earnings per share. The business's revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity

In other Hims & Hers Health news, CEO Andrew Dudum sold 660,000 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the sale, the chief executive officer directly owned 2,214,769 shares in the company, valued at $112,023,016.02. This represents a 22.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 60,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the sale, the insider owned 169,940 shares in the company, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,535,085 shares of company stock valued at $78,035,921 over the last ninety days. 13.71% of the stock is currently owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.